All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubMDS HubMPN HubMultiple Myeloma
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert Opinions

Prof. Gilles Salles | ICML 2017 | L-MIND study, MOR208 + lenalidomide in R/R DLBCL

By Anne Villeneuve
Featured
Gilles Salles
Jun 16, 2017
Share:

L-MIND study, MOR208 + lenalidomide in R/R DLBCL

Share:
More about...
Aggressive B-cell lymphomasDiffuse large B-cell lymphomaICML 2017L-MINDLenalidomideTafasitamab

Related articles

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox